MaxCyte, Inc.
("MaxCyte" or the "Company")
Purchase of Common Stock - PDMR dealing
Gaithersburg, Maryland, November 23, 2021 - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, announces that Richard Douglas, Non-Executive Chairman of MaxCyte, Inc. purchased 20,000 shares on the open market of common stock of the Company ("Common Stock"). The 20,000 shares of Common Stock were purchased at an average price of $11.124 per share ("Purchase"). The Purchase represents approximately 13% of Richard Douglas' aggregate equity and option holdings in the Company's stock capital.
Following the Purchase, Richard Douglas holds 20,000 shares of Common Stock representing 0.02% of the issued stock capital of the Company. Following the Purchase, Richard Douglas holds a further 131,600 options over Common Stock.
The number of unrestricted shares of Common Stock trading under the symbol 'MXCT' is 100,838,137 and the number of restricted shares of Common Stock trading under the symbol 'MXCL' is 330,000.
MaxCyte Contacts:
|
US IR Adviser
Gilmartin Group
David Deuchler, CFA
|
+1 415-937-5400
ir@maxcyte.com
|
|
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
|
+44 (0)20 7886 2500
|
|
UK IR Adviser
Consilium Strategic Communications
Mary-Jane Elliott
Chris Welsh
|
+44 (0)203 709 5700
maxcyte@consilium-comms.com
|
About MaxCyte
MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: three instruments, the ATx™, STx™ and GTx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and/or persons closely associated with them:
|
1
|
Details of the person discharging managerial responsibilities/person closely associated
|
|
a)
|
Name
|
a) Richard Douglas
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
a) Non-Executive Chairman
|
|
b)
|
Initial notification/Amendment
|
Initial Notification
|
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
MaxCyte, Inc.
|
|
b)
|
LEI
|
54930053YHXULRFCU991
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
$0.01 ordinary shares
US57777K1060
|
|
b)
|
Nature of the transaction
|
Purchase of Common Stock
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s) per Ordinary Share
|
Volume(s)
|
|
a) $11.005
b) $11.01
c) $11.03
d) $11.04
e) $11.05
f) $11.06
g) $11.08
h) $11.09
i) $11.1
j) $11.11
k) $11.12
l) $11.13
m) $11.139
n) $11.14
o) $11.15
p) $11.159
|
a) 100
b) 697
c) 360
d) 512
e) 128
f) 64
g) 200
h) 528
i) 300
j) 300
k) 2,400
l) 3,200
m) 1,400
n) 7,000
o) 2,300
p) 511
|
|
|
d)
|
Aggregated information:
· Aggregated volume:
· Price:
|
20,000
N/A
|
|
e)
|
Date of the transaction
|
22 November 2021
|
|
f)
|
Place of the transaction
|
Nasdaq Stock Market
|
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the
United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the
London Stock Exchange use the personal data you provide us, please see our
Privacy Policy.
END
